TissueGen CSO Dr. Kevin Nelson to Present at MD&M Texas

06 May TissueGen CSO Dr. Kevin Nelson to Present at MD&M Texas

“Enabling the Next Generation of Drug Delivery through Implantable Medical Devices” Session on May 8th

WHO: Dr. Kevin Nelson, founder and CSO of TissueGen® Inc., developer of cutting-edge biodegradable polymer technology for implantable drug delivery across a wide variety of therapeutic applications.

WHAT: Dr. Nelson will present a session titled “Enabling the Next Generation of Drug Delivery through Implantable Medical Devices” at MD&M Texas.

The types of drugs and therapeutic agents able to be successfully loaded to fibers for incorporation into implantable medical devices have traditionally been limited by the manufacturing process itself.  Now, the emergence of alternative extrusion methods that occur at room temperature is enabling drug-loading of a wider range of pharmaceutical and biological agents than ever before possible for use in biodegradable implantable devices for localized drug delivery within the body. The incorporation of these drug-loaded fibers into new or existing medical devices can result in faster healing, improved patient compliance, and lower negative outcomes at relatively low cost.

Dr. Nelson’s session will explore the latest advancements in extrusion technology which are enabling the next generation of drug delivery. It will also examine some of the medical applications that stand to be most significantly impacted by this technological advancement, such as spinal cord repair, nerve generation and tumor remediation.

WHERE: MD&M Texas Tech Theater Fort Worth Convention Center Fort Worth, TX

WHEN: Dr. Nelson’s session will take place on Thursday, May 8th, from 12:20-12:50.

About TissueGen

TissueGen® Inc. has more than four decades of cumulative experience in extruding biodegradable polymer fibers with broad drug delivery capabilities. TissueGen offers the medical market innovative technology built upon a portfolio of issued patents for unique drug delivery including the ability to incorporate and elute a broad range of therapeuticsandstandard pharmaceuticals in hydrophobic polymeric fibers or tubes for sustained therapeutic release. For more information, please visit www.tissuegen.com/.

# # #

 

For more information contact:

Jordan Bouclin
SVM Public Relations
401-490-9700
jordan.bouclin@svmpr.com

 

199 Comments

Sorry, the comment form is closed at this time.